1. Home
  2. HRMY vs AZTA Comparison

HRMY vs AZTA Comparison

Compare HRMY & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$28.56

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Azenta Inc.

AZTA

Azenta Inc.

HOLD

Current Price

$24.16

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
AZTA
Founded
2017
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
HRMY
AZTA
Price
$28.56
$24.16
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$46.70
$42.60
AVG Volume (30 Days)
1.1M
884.2K
Earning Date
05-18-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
60.52
EPS
2.71
N/A
Revenue
$868,453,000.00
$593,821,000.00
Revenue This Year
$18.83
$6.25
Revenue Next Year
$12.69
$5.42
P/E Ratio
$10.70
N/A
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$23.98
52 Week High
$40.87
$45.26

Technical Indicators

Market Signals
Indicator
HRMY
AZTA
Relative Strength Index (RSI) 31.12 22.46
Support Level $26.36 N/A
Resistance Level $37.98 $32.18
Average True Range (ATR) 1.89 1.27
MACD -0.55 -0.26
Stochastic Oscillator 21.93 5.44

Price Performance

Historical Comparison
HRMY
AZTA

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About AZTA Azenta Inc.

Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.

Share on Social Networks: